

灯盏细辛中两个新四氢吡喃类化合物

伏继萍*

云南生物谷药业股份有限公司研究院,昆明 650500

摘要:采用硅胶柱色谱、葡聚糖凝胶和高效液相色谱仪从灯盏细辛全草中分离等到2个化合物,根据波谱数据鉴定结构为反式乙酰化灯盏细辛酸甲酯(**1**)和顺式乙酰化灯盏细辛酸甲酯(**2**)。两个化合物皆为新四氢吡喃类化合物。

关键词:灯盏细辛;化学成分;四氢吡喃类化合物

中图分类号:R932

文献标识码:A

DOI:10.16333/j.1001-6880.2016.6.002

Two New Tetrahydropyrans from *Erigeron brevicapus*

FU Ji-ping*

Research Institute of Yunnan Biovalley Pharmaceutical Company LTD., Kunming 650500, China

Abstract: Two compounds were isolated from the whole plant of *Erigeron brevicapus* by silica gel column, Sephadex LH-20 column chromatography and HPLC. Their structures were elucidated on the basis of spectral analysis as trans-methyl brevicatoacetate (**1**) and cis-methyl brevicatoacetate (**2**). These compounds were two new tetrahydropyrans.

Key words: *Erigeron brevicapus*; chemical constituents; tetrahydropyrans

Erigeron brevicapus is a well known traditional Chinese medicine, used to treat a variety of paralysis and its sequelae originated from apoplexy and atherothrombotic of brain^[1]. Flavonoids, caffeoylquinic acids, phenolic compounds and γ -pyrones were previously isolated from this species^[2-4]. In order to further study the chemical constituents of *E. brevicapus*, two new tetrahydropyrans, namely trans-methyl brevicatoacetate (**1**) and cis-methyl brevicatoacetate (**2**) were isolated from it (Fig. 1).




Fig. 1 Chemical structures of compounds 1 and 2

Instruments and Materials

Bruker AV-400 NMR spectrometer; Agilent 1200 LC/MSD Trap SL Mass spectrometer; Shimadzu LC 8A liquid chromatograph; Sephadex LH-20 (GE Healthcare); Silica gel (200-300 mesh, Qingdao, China); The reagents used were of analytical grade or HPLC grade. *Erigeron brevicapus*, collected in Luxi, Yunnan Province of China, was identified by Prof. S. P. Li, Institute of medicinal Plants, Yunnan Agricultural Academy. A voucher specimen (20050291) was deposited at the Research Institute of Yunnan Biovalley Pharmaceutical Company.

Extraction and Isolation

The dried whole plants of *E. breviscapus* (20.0 kg) were extracted with EtOH three times under reflux. After removal of the solvent *in vacuo* to yield a residue (1.8 kg), which was partitioned between H_2O and EtOAc. The EtOAc extract (950 g) was chromatographed on silica gel (200-300 mesh), eluted with a gradient $CHCl_3/MeOH$ (10:1-1:10) to afford fractions F1-F10. Fraction F2 (60 g) was subjected to Sephadex

LH-20 column chromatography (methanol) to afford subfractions F11-F19. Fraction 15 (12 g) was purified repeatedly by preparative and semi-preparative HPLC (95% CH₃OH-H₂O) to give **1** (12.7 mg) and **2** (8.5 mg).

Structural identification

Compound (**1**) was obtained as a yellow oil. HR-ESI-MS *m/z*:549.1379 [M + Na]⁺ (calcd for C₂₇H₂₆O₁₁, 549.1372), indicating 15 degrees of unsaturation. The ¹H NMR, ¹³C NMR spectra (Table 1) indicated the presence of four ester carbonyl groups at (C 170.9 (s), 167.1 (s), 165.9 (s) and 165.2 (s), one me-

thoxyl group at (C 53.2 (q) and (H 3.88 (s, 3H), one methyl at (C 20.7 (q) and (H 2.04 (s, 3H), a methylene (C 38.2 (t) and (H 2.57 (m, 2H), and at least five oxygenated carbons. The methylene (C-2) was analyzed as the starting point. In the COSY spectrum, five strong cross peak was found from 2H-2/H-3, H-3/H-4, H-4/H-5, H-5/H-6, H-6/2H-9, it proved the existence of a partial structure -CH₂-CH-CH-CH-CH-CH₂-. In addition, the carbon and proton chemical shifts pointed out that the back five carbons bear oxygen group, except C-2. Compared the spectral data of erigoster A^[5] with compound **1**, both have the same mother nucleus.

Table 1 ¹H NMR and ¹³C NMR of compound 1 and 2 in CD₃Cl (400 MHz. (in ppm)

C	δ _H		δ _C	
	1	2	1	2
1	–	–	103.5 (s)	103.4 (s)
2	2.60 (2H. m)	2.57 (2H. m)	38.2 (t)	38.2 (t)
3	5.83 (1H. J=4.8 Hz. t)	5.81 (1H. m)	64.7 (d)	64.7 (d)
4	5.59 (1H, J=5.2 Hz. t)	5.48 (1H. J=5.2 Hz. t)	66.7 (d)	66.7 (d)
5	4.81 (1H. m)	4.69 (1H. m)	74.8 (d)	74.8 (d)
6	4.59 (1H, J=5.2 Hz. t)	4.53 (1H, J=6.0 Hz. t)	78.8 (d)	79.1 (d)
9	4.59 (2H. m)	4.71 (2H. m)	62.4 (t)	61.9 (t)
10	–	–	167.1 (s)	167.1 (s)
9-OAc	–	–	170.9 (s)	170.5 (s)
	2.04 (3H. s)	2.07 (3H. s)	20.7 (q)	20.8 (q)
10-OCH3	3.88 (3H. s)	3.87 (3H. s)	53.2 (q)	53.1 (q)
1'	–	–	165.9 (s)	166.0 (s)
2'	–	–	129.6 (s)	129.6 (s)
3',7'	8.07 (2H, J=7.2 Hz. d)	8.06 (2H, J=7.2 Hz. d)	129.9 (d)	129.8 (d)
4',6'	7.45 (2H, J=7.6 Hz. d)	7.47 (2H, J=7.6 Hz. d)	128.6 (d)	128.6 (d)
5'	7.58 (1H, J=7.2 Hz. t)	7.60 (1H, J=7.2 Hz. t)	133.4 (d)	133.4 (d)
1''	–	–	165.2 (s)	164.2 (s)
2''	7.44 (1H. J=16.0 Hz. d)	6.86 (1H, J=12.8 Hz. d)	146.4 (d)	146.4 (d)
3''	6.12 (1H. J=16.0 Hz. d)	5.64 (1H, J=12.8 Hz. d)	113.3 (d)	114.7 (d)
4''	–	–	126.5 (s)	127.0 (s)
5'',9''	7.24 (2H, J=8.4 Hz. d)	7.65 (2H. J=8.8 Hz. d)	130.2 (d)	132.8 (d)
6'',8''	6.76 (2H. J=8.4 Hz. d)	6.79 (2H, J=8.8 Hz. d)	115.9 (d)	115.1 (d)
7''	–	–	158.3 (s)	157.1 (s)

The HMBC correlations (Fig. 2) of 3H-methyl, 2H-9 with the carbonyl group δC 170.9 (s), indicated that

an acetoxy located at C-9. The HMBC correlations of 3H-methoxy group with C-10(167.1, s) showed that a

methyl ester could be positioned C-1^[6]. The benzoyloxy group was assigned to C-3 by the HMBC correlations from H-3, and 2H-3',7' to the corresponding C-1' (165.9, s). The phenacryloyloxy group was attached to C-4 by HMBC the correlations of H-4, H-2'' and H-3'' with C-1'' (165.2, s), of H-3'' with C-4'' (Fig. 2). For the above mentioned groups occupied 10 oxygens in the molecular formula, the remaining oxygen as a hydroxyl group was attributed to a benzene ring carbon in downfield from the phenacryloyloxy group, the location of the hydroxyl group at C-7'' was deduced from the HMBC correlations of 2H-5'',9'', and 2H-6'',8'' with C-7'' (158.3, s). In addition, the coupling constant of the double bond between C-2'' and C-3'' in **1** was 16 Hz, it belonged to the trans coupling in olefines. On the basis of the above evidence, the structure of **1** was determined as shown, and this compound has been given the name trans-methyl brevicatoacetate. The coupling constant between H-5 β and H-6 β indicated a preferred α -orientation for the substituent group at C-6 position^[7]. NMR spectra and detailed experimental data of **1** is available free of charge via the Internet at <http://www.trew.ac.cn>.




Fig. 2 Key HMBC correlations of compound 1

Compound (**2**) was isolated as a yellow oil. The molecular formula was established as C₂₇H₂₈O₁₁ by HR-ESI-MS m/z : 549. 1378 [M + Na]⁺ (calcd. 549. 1372), including fifteen degrees of unsaturation. The ¹H NMR and ¹³C NMR (Table 1) exhibited the presence of one

acetate system [(H 2.07 (3H, s), (C 20.8 (q) and (C 170.5 (s))], a methyl ester moiety [(H 3.87 (3H, s), (C 53.2 (q) and 167.1 (s))], a benzoyloxy group, a phenacryloyloxy group, These spectral features suggested **2** had the same structure as **1**, the only significant difference of **1** and **2** was the coupling constant of the double bond between C-2'' and C-3''. The coupling constant of **2** was 12.8 Hz, in the range of the cis coupling 6 ~ 12 Hz. Consequently, the structure of **2** was established, and it has been accorded the name cis-methyl brevicatoacetate. NMR spectra and detailed experimental data of **2** is available free of charge via the Internet at <http://www.trew.ac.cn>.

References

- Jiang ZY, Liu SP, Qu T. Determination of the dissolution of breviscapinun tablets. *Chin Pharm*, 2011, 14: 1014-1016.
- Zhang WD, Chen WS, Wang YH, *et al.* Studies of flavonoids from *Erigeron brevicapus*. *Chin J Chin Mater Med*, 2000, 9: 536-538.
- Merfort I. Caffeoylquinic acids from flowers of *Arnica montana* and *Arnica chamissonis*. *Phytochemistry*, 1992, 31: 2111-2113.
- Zhang WD, Thi Bang Tam HA, Chen WS, *et al.* Study on structure and biological activity of new phenolic acids from *Erigeron brevicapus*. *Acta Pharm Sin*, 2001, 5: 360-363.
- Yue JM, Zhao QS, Lin ZW, *et al.* Phenolic compounds from *Erigeron breviscapus*. *Acta Botan Sin*, 2000, 42: 311-315.
- Zhao QS, Sun HD, Peng YL. Fleabane ester b and its preparation method and application in pharmaceutical. CN 1462750A, 2003-12-14.
- Du J, Lin YH, Lin YH. Methyl brevicate extracted from *Erigeron breviscapus* and its medical application for treating cardiovascular and cerebrovascular diseases. CN101974011A, 2011-02-16.